Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
Episode 7 · Dec 16, 2024, 08:43 PM
Share
Subscribe
This supplement to The American Journal of Managed Care explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches.
To view the article and claim CE credit for this activity, click here.
Program Description
Although treatments for schizophrenia have improved in recent decades, many standard treatments still have significant limitations. Treating schizophrenia requires a personalized approach beyond just medication, including early intervention to improve outcomes and prevent relapse as well as care coordination to ensure adherence and symptom management. Both negative and cognitive symptoms are central aspects of schizophrenia treatment, but traditional antipsychotic medications have limited efficacy against these symptoms. Additionally, the lack of recently updated guidelines for managing therapies in patients with schizophrenia has created barriers to treatment. This supplement explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches. By facilitating appropriate use and access to emerging schizophrenia therapies, including prescription digital therapeutics, managed care professionals can play an important role in individualizing therapy and improving access to medications.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: August 30, 2024
Expiration date: September 30, 2025
Time to complete activity: 3.0 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
To view the article and claim CE credit for this activity, click here.
Program Description
Although treatments for schizophrenia have improved in recent decades, many standard treatments still have significant limitations. Treating schizophrenia requires a personalized approach beyond just medication, including early intervention to improve outcomes and prevent relapse as well as care coordination to ensure adherence and symptom management. Both negative and cognitive symptoms are central aspects of schizophrenia treatment, but traditional antipsychotic medications have limited efficacy against these symptoms. Additionally, the lack of recently updated guidelines for managing therapies in patients with schizophrenia has created barriers to treatment. This supplement explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches. By facilitating appropriate use and access to emerging schizophrenia therapies, including prescription digital therapeutics, managed care professionals can play an important role in individualizing therapy and improving access to medications.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: August 30, 2024
Expiration date: September 30, 2025
Time to complete activity: 3.0 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain positive, negative, and cognitive symptoms of schizophrenia and the unmet needs in the management of schizophrenia.
- Explore the pharmacology, safety profiles, and clinical pearls of new and emerging therapies for the management of schizophrenia.
- Analyze clinical trial data of recently approved and emerging therapies and how they fit into the treatment paradigm of schizophrenia.
- Investigate value-based approaches to improve access to individualized treatment plans to address the clinical and economic burdens of disease.